Ulcerative Colitis Clinical Trials in Phoenix

Showing 261-280 of 317 trials

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293

This phase I trial is studying the side effects and best dose of TLR8 agonist VTX-2337 and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Biological therapies, such as TLR8 agonist VTX-2337, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TLR8 agonist VTX-2337 together with pegylated liposomal doxorubicin hydrochloride or paclitaxel may kill more tumor cells.

Malignant Ovarian Mixed Epithelial TumorOvarian Brenner TumorOvarian Clear Cell Cystadenocarcinoma+7 more

Gynecologic Oncology Group20 participantsStarted Mar 2011

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Aurora, Colorado, United States +7 more locations

COMPLETEDNA11 miles

Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

NCT00130715

The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic abscess within 6 months postoperatively.

Intestinal ObstructionDigestive System Surgical Procedures

Genzyme, a Sanofi CompanyStarted Jun 1998

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +18 more locations

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

Ulcerative Colitis Trials in Other Cities

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

Dose Ranging Study

Dose Ranging and Dose Frequency of LIPO-102

Tiotropium / Respimat One-Year Study

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

12 / 48 Week Pivotal PFT vs PBO in COPD I

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Other Conditions in Phoenix